Relationships of single nucleotide polymorphisms of monocyte chemoattractant protein 1 and chemokine receptor 2 with susceptibility and clinicopathologic characteristics of neoplasia of uterine cervix in Taiwan women

Reproductive Sciences

Volumn 20, Issue 10, 2013, Pages 1175-1183

  Wu, Hsin Hung ^a,b   Lee, Tsung Hsien ^b   Tee, Yi Torng ^b   Chen, Shiuan Chih ^b,c   Yang, Shun Fa ^b,c   Lee, Shu Kuei ^b,c   Ko, Jiunn Liang ^b   Wang, Po Hui ^b  

^a CHANGHUA CHRISTIAN HOSPITAL   (Taiwan)

^b CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^c CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

cervical cancer; chemokine receptor 2; monocyte chemoattractant protein 1; single nucleotide polymorphisms; Taiwan women

Indexed keywords

CHEMOKINE RECEPTOR CCR2; GENOMIC DNA; MONOCYTE CHEMOTACTIC PROTEIN 1;

ARTICLE; CANCER STAGING; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; DNA EXTRACTION; DNA POLYMORPHISM; DYSPLASIA; FEMALE; GENE EXPRESSION; GENETIC ASSOCIATION; GENETIC RISK; GENOTYPING TECHNIQUE; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; TAIWAN; TUMOR INVASION; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA;

CERVICAL CANCER; CHEMOKINE RECEPTOR 2; MONOCYTE CHEMOATTRACTANT PROTEIN 1; SINGLE NUCLEOTIDE POLYMORPHISMS; TAIWAN WOMEN;

ADULT; AGED; CERVICAL INTRAEPITHELIAL NEOPLASIA; CERVIX UTERI; CHEMOKINE CCL2; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MIDDLE AGED; NEOPLASM INVASIVENESS; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, CCR2; TAIWAN;

EID: 84882601629     PISSN: 19337191     EISSN: 19337205     Source Type: Journal    
DOI: 10.1177/1933719113477481     Document Type: Article

References (48)

1. Nasiell K, Roger V, Nasiell M. Behavior of mild cervical dysplasia during long term follow-up. Obstet Gynecol. 1986 ; 67 (5). 665-669
2. Petignat P, Roy M. Diagnosis and management of cervical cancer. Br Med J. 2007 ; 335 (7623). 765-768
3. Pinto AP, Crum CP. Natural history of cervical neoplasia: defining progression and its consequence. Clin Obstet Gynecol. 2000 ; 43 (2). 352-362
4. Valente AJ, Graves DT, Vialle-Valentin CE, Delgado R, Schwartz CJ. Purification of a monocyte chemotactic factor secreted by nonhuman primate vascular cells in culture. Biochemistry. 1988 ; 27 (11). 4162-4168
5. Matsushima K, Larsen CG, DuBois GC, Oppenheim JJ. Purification and characterization of a novel monocyte chemotactic and activating factor produced by a human myelomonocytic cell line. J Exp Med. 1989 ; 169 (4). 1485-1490
6. Rovin BH, Lu L, Saxena R. A novel polymorphism in the MCP-1 gene regulatory region that influences MCP-1 expression. Biochem Biophys Res Commun. 1999 ; 259 (2). 344-348
7. Craig MJ, Loberg RD. CCL2 (monocyte chemoattractant protein-1) in cancer bone metastases. Cancer Metastasis Rev. 2006 ; 25 (4). 611-619
8. Booth G, Newham P, Barlow R, Raines S, Zheng B, Han S. Gene expression profiles at different stages of collagen-induced arthritis. Autoimmunity. 2008 ; 41 (7). 512-521
9. Takahashi M, Galligan C, Tessarollo L Yoshimura. Monocyte chemoattractant protein-1 (MCP-1), not MCP-3, is the primary chemokine required for monocyte recruitment in mouse peritonitis induced with thioglycollate or zymosan A. J Immunol. 2009 ; 183 (5). 3463-3471
10. Charo IF, Taubman MB. Chemokines in the pathogenesis of vascular disease. Circ Res. 2004 ; 95 (9). 858-866
11. Riethdorf L, Riethdorf S, Gützlaff K, Prall F, Löning T. Differential expression of the monocyte chemoattractant protein-1 gene in human apillomavirus-16-infected squamous intraepithelial lesions and squamous cell carcinomas of the cervix uteri. Am J Pathol. 1996 ; 149 (5). 1469-1476
12. Arenberg DA, Keane MP, DiGiovine B, et al. Macrophage infiltration in human non-small-cell lung cancer: the role of CC chemokines. Cancer Immunol Immunother. 2000 ; 49 (2). 63-70
13. Ueno T, Toi M, Saji H, et al. Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer. Clin Cancer Res. 2000 ; 6 (8). 3282-3289
14. Smith MW, Carrington M, Winkler C, et al. CCR2 chemokine receptor and AIDS progression. Nat Med. 1997 ; 3 (10). 1052-1053
15. Kurihara T, Warr G, Loy J, Bravo R. Defects in macrophage recruitment and host defense in mice lacking the CCR2 chemokine receptor. J Exp Med. 1997 ; 186 (10). 1757-1762
16. MacKay CR. Chemokines: immunology's high impact factors. Nat Immunol. 2001 ; 2 (2). 95-101
17. Negus RP, Stamp GW, Relf MG, et al. The detection and localization of monocyte chemoattractant protein-1 (MCP-1) in human ovarian cancer. J Clin Invest. 1995 ; 95 (5). 2391-2396
18. Expression of monocyte chemotactic protein-1 in human invasive ductal breast cancer. Pathol Res Pract. 1998 ; 194 (5). 335-340
19. Liss C, Fekete MJ, Hasina R, Lam CD, Lingen MW. Paracrine angiogenic loop between head-and-neck squamous-cell carcinomas and macrophages. Int J Cancer. 2001 ; 93 (6). 781-785
20. Strauss L, Volland D, Guerrero A, Reichert T. Antiangiogenic and anti-immunosuppressive therapeutic strategies in human head and neck squamous cell carcinoma (HNSCC). Mund Kiefer Gesichtschir. 2005 ; 9 (5). 273-281
21. Kleine-Lowinski K, Gillitzer R, Kuhne-Heid R. Monocyte-chemo-attractant- protein-1 (MCP-1)-gene expression in cervical intra-epithelial neoplasias and cervical carcinomas. Int J Cancer. 1999 ; 82 (1). 6-11
22. Enjuanes A, Benavente Y, Bosch F, et al. Genetic variants in apoptosis and immunoregulation-related genes are associated with risk of chronic lymphocytic leukemia. Cancer Res. 2008 ; 68 (24). 10178-10186
23. Vazquez-Lavista LG, Lima G, Gabilondo F, Llorente L. Genetic association of monocyte chemoattractant protein 1 (MCP-1)-2518 polymorphism in Mexican patients with transitional cell carcinoma of the bladder. Urology. 2009 ; 74 (2). 414-418
24. Chen MK, Yeh KT, Chiou HL, Lin CW, Chung TT, Yang SF. CCR2-64I gene polymorphism increase susceptibility to oral cancer. Oral Oncol. 2011 ; 47 (7). 577-582
25. Coelho A, Matos A, Catarino R, et al. Protective role of the polymorphism CCR2-64I in the progression from squamous intraepithelial lesions to invasive cervical carcinoma. Gynecol Oncol. 2005 ; 96 (3). 760-764
26. Ivansson EL, Gustavsson IM, Magnusson JJ, et al. Variants of chemokine receptor 2 and interleukin 4 receptor, but not interleukin 10 or Fas ligand, increase risk of cervical cancer. Int J Cancer. 2007 ; 121 (11). 2451-2457
27. Michiels K, Schutyser E, Conings R, et al. Carcinoma cell-derived chemokines and their presence in oral fluid. Eur J Oral Sci. 2009 ; 117 (4). 362-368
28. Koide N, Nishio A, Sato T, Sugiyama A, Miyagawa S. Significance of macrophage chemoattractant protein-1 expression and macrophage infiltration in squamous cell carcinoma of the esophagus. Am J Gastroenterol. 2004 ; 99 (9). 1667-1674
29. Marcus B, Arenberg D, Lee J, et al. Prognostic factors in oral cavity and oropharyngeal squamous cell carcinoma. Cancer. 2004 ; 101 (12). 2779-2787
30. Strieter RM, Burdick MD, Gomperts BN, Belperio JA, Keane MP. CXC chemokines in angiogenesis. Cytokine Growth Factor Rev. 2005 ; 16 (6). 593-609
31. Coelho A, Matos A, Catarino R, et al. The influence of chemokine receptor CCR2 genotypes in the route to cervical carcinogenesis. Gynecol Obstet Invest. 2007 ; 64 (4). 208-212
32. Chatterjee K, Dandara C, Hoffman M, Williamson AL. CCR2-V64I polymorphism is associated with increased risk of cervical cancer but not with HPV infection or pre-cancerous lesions in African women. BMC Cancer. 2010 ; 10: 278
33. Evidence for the role of the carboxyl-terminal tail in receptor trafficking. J Biol Chem. 1997 ; 272 (2). 1038-1045
34. Kostrikis LG, Huang Y, Moore JP, et al. A chemokine receptor CCR2 allele delays HIV-1 disease progression and is associated with a CCR5 promoter mutation. Nat Med. 1998 ; 4 (3). 350-353
35. Nakayama EE, Tanaka Y, Nagai Y, Iwamoto A, Shioda T. A CCR2-V64I polymorphism affects stability of CCR2A isoform. AIDS. 2004 ; 18 (5). 729-738
36. Sanders SK, Crean SM, Boxer PA, Kellner D, LaRosa GJ, Hunt SW. Functional differences between monocyte chemotactic protein-1 receptor A and monocyte chemotactic protein-1 receptor B expressed in a Jurkat T cell. J Immunol. 2000 ; 165 (9). 4877-4883
37. Zheng B, Wiklund F, Gharizadeh B, et al. Genetic polymorphism of chemokine receptors CCR2 and CCR5 in Swedish cervical cancer patients. Anticancer Res. 2006 ; 26 (5B). 3669-3674
38. Gonzalez E, Rovin BH, Sen L, et al. HIV-1infection and AIDS dementia are influenced by a mutant MCP-1 allele linked to increased monocyte infiltration of tissues and MCP-1 levels. Proc Natl Acad Sci U S A. 2002 ; 99 (21). 13795-13800
39. Tse KP, Tsang NM, Chen KD, et al. MCP-1 promoter polymorphism at 2518 is associated with metastasis of nasopharyngeal carcinoma after treatment. Clin Cancer Res. 2007 ; 13 (21). 6320-6326
40. Zhang J, Patel L, Pienta KJ. CC chemokine ligand 2 (CCL2) promotes prostate cancer tumorigenesis and metastasis. Cytokine Growth Factor Rev. 2010 ; 21 (1). 41-48
41. Vicari AP, Caux C. Chemokines in cancer. Cytokine Growth Factor Rev. 2002 ; 13 (2). 143-154
42. Tang CH, Tsai CC. CCL2 increases MMP-9 expression and cell motility in human chondrosarcoma cells via the Ras/Raf/MEK/ERK/NF-κB signaling pathway. Biochem Pharmacol. 2012 ; 83 (3). 335-344
43. Hussain A, Harish G, Prabhu SA, et al. Inhibitory effect of genistein on the invasive potential of human cervical cancer cells via modulation of matrix metalloproteinase-9 and tissue inhibitors of matrix metalloproteinase-1 expression. Cancer Epidemiol. 2012 ; 36 (6). e387 - e393
44. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer. 2002 ; 2 (3). 161-174
45. Scherer RL, McIntyre JO, Matrisian LM. Imaging matrix metalloproteinases in cancer. Cancer Metastasis Rev. 2008 ; 27 (4). 679-690
46. Chiu HY, Sun KH, Chen SY, et al. Autocrine CCL2 promotes cell migration and invasion via PKC activation and tyrosine phosphorylation of paxillin in bladder cancer cells. Cytokine. 2012 ; 59 (2). 423-432
47. Tabara Y, Kohara K, Yamamoto Y, et al. Polymorphism of the monocyte chemoattractant protein (MCP-1) gene is associated with the plasma level of MCP-1 but not with carotid intima-media thickness. Hypertens Res. 2003 ; 26 ((9 )). 677-683
48. Kucukgergin C, Isman FK, Cakmakoglu B, Sanli O, Seckin S. Association of polymorphisms in MCP-1, CCR2, and CCR5 genes with the risk and clinicopathological characteristics of prostate cancer. DNA Cell Biol. 2012 ; 31 ((8 )). 1418-1424